Primary source: European Medicines Agency (EMA)
Stakeholders must adapt signal management workflows for herbal products to meet specific detection and assessment criteria as outlined in the reflection paper.
Improving safety signal detection and assessment for herbal medicinal products is crucial given their unique complexities, ultimately enhancing patient safety.
Implement increased documentation and reporting processes for traditional herbal medicinal products. Ensure staff receive training on the complexities involved in signal management for these products.
Regulatory Intelligence Lead
Review before 2026-10-31.
Guidance on handling complex botanical data and bridging gaps in spontaneous reporting for signal management.
Stakeholders must adapt signal management workflows for herbal products to incorporate specific detection and assessment criteria.
May require additional training for staff regarding herbal product safety signals.
Increased emphasis on documentation and reporting for traditional herbal medicinal products due to complexity of constituents.
Possible changes in local legislation and compliance practices for herbal products.
Need to align national regulations with EU guidelines on herbal medicinal products.
Implement increased documentation and reporting processes for traditional herbal medicinal products. Ensure staff receive training on the complexities involved in signal management for these products.
The European Medicines Agency has released a reflection paper focusing on safety signal management for traditional herbal medicinal products. Stakeholders are required to adapt their signal management workflows to address the unique challenges posed by the complexity of constituents in these products. There is a public consultation starting on July 15, 2026, with a deadline for comments set for October 15, 2026.
What changed: Stakeholders must adapt signal management workflows for herbal products to meet specific detection and assessment criteria as outlined in the reflection paper.
Why it matters: Improving safety signal detection and assessment for herbal medicinal products is crucial given their unique complexities, ultimately enhancing patient safety.
Practical implication: Implement increased documentation and reporting processes for traditional herbal medicinal products. Ensure staff receive training on the complexities involved in signal management for these products.
Published from the Firecrawl policy change extraction pipeline.
Monitor and evaluate the drug misuse trends and health impacts associated with ketamine, focusing on the increase in seizures as part of public health and law enforcement strategies.
Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.
Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.
The marketing authorization holder must submit amended product information reflecting the new safety guidelines by October 9, 2026, with translations due by August 10, 2026.
